Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

39.60 +0.49 (+1.25%)
Streaming Delayed Price Updated: 11:21 AM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study showed significant weight loss and improved glycemic status in participants, with... 
Via Benzinga
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
From Genentech
Via Business Wire
Can Ocugen Stock Keep Churning Higher?
This tiny biotech caught fire in 2024. Can it sustain the momentum? 
Via The Motley Fool
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving... 
Via Benzinga
Exposures Product Safety
2 Small-Cap Growth Stocks With Room To Run
These two small-cap growth stocks could be ready to run. 
Via The Motley Fool
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
From Genentech
Via Business Wire
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
From Genentech
Via Business Wire
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx. 
Via Benzinga
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
From Genentech
Via Business Wire
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
Think globally with this high-yielding ETF. 
Via The Motley Fool
Topics ETFs
Why Roche Holdings Stock Popped Today
Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate. 
Via The Motley Fool
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Recursion is playing the long game with its AI-focused approach to drug discovery and development. 
Via The Motley Fool
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood... 
Via Benzinga
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming. 
Via Investor's Business Daily
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend. 
Via InvestorPlace
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-positive adult patients. Enspryng's Phase 3 study results disappoint. Vyvgart... 
Via Benzinga
Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B
Lonza expands biologics manufacturing capacity with acquisition of Genentech facility in Vacaville, CA. $1.2 billion deal includes employee retention and facility upgrades. Transaction expected to... 
Via Benzinga
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with... 
Via Benzinga
Exposures Product Safety
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets. 
Via Benzinga
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... 
Via Talk Markets
Exposures Product Safety
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at... 
Via Benzinga
Exposures Product Safety
Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges
Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in blood pressure observed, with optimistic outlook on upcoming ACC event. 
Via Benzinga
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment
The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks. 
Via Investor's Business Daily
This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies
Results from Roche's Phase 3 OUtMATCH study on Xolair for multi-food allergies. Published in NEJM, the study reveals increased tolerance in patients aged 1-55. FDA-approved expanded use for... 
Via Benzinga
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies
From Genentech
Via Business Wire
Move Over Magnificent 7, Say Hello to the GRANOLAS
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. 
Via InvestorPlace
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024. 
Via Benzinga
Exposures Product Safety
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
From Genentech
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.